


1626

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0654-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Please type a plus sign (+) inside this box → ☐

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/856,009	
	Filing Date	May 16, 2001	
	First Named Inventor	Kozak et al.	
	Group Art Unit	2594	
	Examiner Name	Sonya N. Wright	
Total Number of Pages in This Submission	33	Attorney Docket Number	800.1012

RECEIVED
MAR 07 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	- return receipt postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Name	Davidson, Davidson & Kappel, LLC				
Address	485 Seventh Avenue, 14 th Floor				
City	New York	State	NY	Zip Code	10018
Country	USA	Telephone	(212) 736-1940	Fax	(212) 736-2427
Individual name	Morey B. Wildes				
Signature					
Date	February 26, 2003				

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: February 26, 2003			
Typed or printed name	Morey B. Wildes		
Signature		Date	February 26, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: KOZAK, et al.

Serial No.: 09/856,009

Filed: May 16, 2001

For:

**PHOSPHOLIPID DERIVATIVES OF
NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS**

Examiner:

Sonya N. Wright (Group Art Unit: 1626)

RECEIVED

MAR 07 2003

TECH CENTER 1600/2900

Box: NON-FEE AMENDMENT
Commissioner for Patents
Washington, D.C. 20231

February 26, 2003

SUPPLEMENTAL PRELIMINARY AMENDMENT

S I R:

Preliminary to examination, please amend the above-identification as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 2, line 29 with the following rewritten paragraph:

a1 Diclofenac ([o-[(2,6-dichlorophenyl)amino]phenyl]acetate) is a non-steroidal anti-inflammatory drug of the phenylacetic acid class. When given orally the absorption of diclofenac is rapid and complete. It binds extensively to plasma albumin. Substantial concentrations of drug are attained in synovial fluid, which is the proposed site of action of the NSAIDs. Diclofenac is a potent inhibitor of prostaglandin synthesis and has also been shown to inhibit interleukin-1 (IL-1 β) and tumor necrosis factor alpha (TNF- α), involved in osteoarthritis. Gastrointestinal complications such as ulceration and intolerance are the most common adverse effect of diclofenac. Renal dysfunction and hypersensitivity reactions also occur. Many patients with